Clinicians can safely use Bioidentical Hormone Replacement Therapy to treat age-related hormonal imbalances in both males and females
Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, et al
Chalmers RA, et al

KFF health tracking poll May 2024: The publics use and views of GLP-1 drugs, KFF (2024) Discontinuation and reinitation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity, JAMA Network (2025) Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks, Obesity Pillars (2024) Medication adherence and characteristics of patients who spend less on basic needs to afford medications, Journal of the American Board of Family Medicine (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity, JAMA Network (2021) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes, JAMA Network (2022) Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery, Obesity (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Common Side Effects of Ozempic The most frequently reported side effects of Ozempic are gastrointestinal in nature, including: Nausea Vomiting Diarrhea Constipation Abdominal pain These side effects are often temporary and may diminish over time as the body adjusts to the medication
Zepbound (tirzepatide) is a newer medication that acts as a dual agonist